Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy

Status Completed

Clinical Trial Summary

The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors. Since those tumors can belong to a variety of entities the therapeutic consequences also show considerable variation. In order to definitely determine the type of tumor, invasive procedures like CT guided biopsies are often required, which could be avoided by a tumor specific imaging method. The presently available scintigraphic procedures are either time consuming and lead to high radiation exposure or are technically demanding. The steroidogenic enzymes CYP11B1 (11ß-hydroxylase)and CYP11B2 (aldosterone synthase)are expressed exclusively in the adrenal cortex and therefore represent suitable targets for a specific imaging technique. In our project we evaluate 123I-Iodometomidate which binds to both CYP11B enzymes as radiotracer for adrenal scintigraphy.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00454103
Study type	Interventional
Source	University of Wuerzburg
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	March 2007
Completion date	February 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04373265` - Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)	Phase 1
Recruiting	`NCT06050057` - Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
Recruiting	`NCT06066333` - Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma	Phase 2
Recruiting	`NCT03127774` - Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma	Phase 2
Completed	`NCT01048892` - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features	Phase 1
Recruiting	`NCT00457587` - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
Recruiting	`NCT00669266` - Adrenal Tumors - Pathogenesis and Therapy
Recruiting	`NCT05999292` - Phase 1 Study of 68Ga-R8760	Phase 1
Completed	`NCT05361083` - First-in-human Evaluation of [18F]CETO	Early Phase 1
Recruiting	`NCT05660889` - Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma
Completed	`NCT00003038` - Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors	Phase 1
Enrolling by invitation	`NCT03474237` - A Prospective Cohort Study for Patients With Adrenal Diseases
Recruiting	`NCT04119024` - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors	Phase 1
Enrolling by invitation	`NCT05036434` - Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma	Phase 2
Terminated	`NCT05012397` - Milademetan in Advanced/Metastatic Solid Tumors	Phase 2
Not yet recruiting	`NCT06333314` - Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI	Phase 2
Withdrawn	`NCT00469469` - Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma	Phase 2
Completed	`NCT00002608` - Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors	Phase 2
Not yet recruiting	`NCT05839886` - The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma
Recruiting	`NCT05634577` - A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma	Phase 2